{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:01:52Z","timestamp":1792425712518,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI149502"],"award-info":[{"award-number":["R01AI149502"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001774","name":"New Jersey Health Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-025-08793-3","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T14:49:11Z","timestamp":1756824551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pre-existing YFV-17D immunity mediates T cell cross-protection against dengue virus serotype 2 infection in mice"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8328-9062","authenticated-orcid":false,"given":"Prince Baffour","family":"Tonto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Gallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Alatrash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Kung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4588-3360","authenticated-orcid":false,"given":"Bobby Brooke","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"8793_CR1","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41564-020-0714-0","volume":"5","author":"TC Pierson","year":"2020","unstructured":"Pierson, T. C. & Diamond, M. S. The continued threat of emerging flaviviruses. Nat. Microbiol. 5, 796\u2013812 (2020).","journal-title":"Nat. Microbiol."},{"key":"8793_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1800820","volume":"379","author":"S Sridhar","year":"2018","unstructured":"Sridhar, S. et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N. Engl. J. Med. 379, 327\u2013340 (2018).","journal-title":"N. Engl. J. Med."},{"key":"8793_CR3","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3389\/fimmu.2020.01055","volume":"11","author":"AM Izmirly","year":"2020","unstructured":"Izmirly, A. M., Alturki, S. O., Alturki, S. O., Connors, J. & Haddad, E. K. Challenges in dengue vaccines development: pre-existing infections and cross-reactivity. Front. Immunol. 11, 1055 (2020).","journal-title":"Front. Immunol."},{"key":"8793_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/vaccines8020266","volume":"8","author":"A Pattnaik","year":"2020","unstructured":"Pattnaik, A., Sahoo, B. R. & Pattnaik, A. K. Current status of Zika virus vaccines: successes and challenges. Vaccines 8, 266 (2020).","journal-title":"Vaccines"},{"key":"8793_CR5","doi-asserted-by":"publisher","first-page":"l5710","DOI":"10.1136\/bmj.l5710","volume":"367","author":"DJ Gubler","year":"2019","unstructured":"Gubler, D. J. & Halstead, S. B. Is Dengvaxia a useful vaccine for dengue endemic areas? Bmj 367, l5710 (2019).","journal-title":"Bmj"},{"key":"8793_CR6","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","volume":"15","author":"SJ Thomas","year":"2019","unstructured":"Thomas, S. J. & Yoon, I. K. A review of Dengvaxia\u00ae: development to deployment. Hum. Vaccin Immunother. 15, 2295\u20132314 (2019).","journal-title":"Hum. Vaccin Immunother."},{"key":"8793_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.tmaid.2019.05.002","volume":"30","author":"MJ Luppe","year":"2019","unstructured":"Luppe, M. J. et al. Yellow fever (YF) vaccination does not increase dengue severity: a retrospective study based on 11,448 dengue notifications in a YF and dengue endemic region. Travel Med. Infect. Dis. 30, 25\u201331 (2019).","journal-title":"Travel Med. Infect. Dis."},{"key":"8793_CR8","doi-asserted-by":"publisher","first-page":"e0009907","DOI":"10.1371\/journal.pntd.0009907","volume":"15","author":"AC Vicente Santos","year":"2021","unstructured":"Vicente Santos, A. C. et al. Yellow fever vaccine protects mice against Zika virus infection. PLoS Negl. Trop. Dis. 15, e0009907 (2021).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"8793_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41564-024-01903-7","volume":"10","author":"S Kalimuddin","year":"2025","unstructured":"Kalimuddin, S. et al. Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans. Nat. Microbiol. 10, 374\u2013387 (2025).","journal-title":"Nat. Microbiol."},{"key":"8793_CR10","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3389\/fimmu.2020.00334","volume":"11","author":"APS Rathore","year":"2020","unstructured":"Rathore, A. P. S. & St John, A. L. Cross-reactive immunity among flaviviruses. Front. Immunol. 11, 334 (2020).","journal-title":"Front. Immunol."},{"key":"8793_CR11","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/ni.3515","volume":"17","author":"W Dejnirattisai","year":"2016","unstructured":"Dejnirattisai, W. et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat. Immunol. 17, 1102\u20131108 (2016).","journal-title":"Nat. Immunol."},{"key":"8793_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15674","volume":"8","author":"P Pantoja","year":"2017","unstructured":"Pantoja, P. et al. Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus. Nat. Commun. 8, 15674 (2017).","journal-title":"Nat. Commun."},{"key":"8793_CR13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1126\/science.aav6618","volume":"363","author":"I Rodriguez-Barraquer","year":"2019","unstructured":"Rodriguez-Barraquer, I. et al. Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. Science 363, 607\u2013610 (2019).","journal-title":"Science"},{"key":"8793_CR14","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1126\/science.abb6143","volume":"369","author":"LC Katzelnick","year":"2020","unstructured":"Katzelnick, L. C. et al. Zika virus infection enhances future risk of severe dengue disease. Science 369, 1123\u20131128 (2020).","journal-title":"Science"},{"key":"8793_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102738","volume":"54","author":"R Shukla","year":"2020","unstructured":"Shukla, R. et al. Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement. EBioMedicine 54, 102738 (2020).","journal-title":"EBioMedicine"},{"key":"8793_CR16","doi-asserted-by":"publisher","first-page":"e0009641","DOI":"10.1371\/journal.pntd.0009641","volume":"15","author":"CM Crooks","year":"2021","unstructured":"Crooks, C. M. et al. Previous exposure to dengue virus is associated with increased Zika virus burden at the maternal-fetal interface in rhesus macaques. PLoS Negl. Trop. Dis. 15, e0009641 (2021).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"8793_CR17","doi-asserted-by":"publisher","first-page":"e0011710","DOI":"10.1371\/journal.pntd.0011710","volume":"17","author":"CF Estofolete","year":"2023","unstructured":"Estofolete, C. F. et al. Influence of previous Zika virus infection on acute dengue episode. PLoS Negl. Trop. Dis. 17, e0011710 (2023).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"8793_CR18","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.ijid.2023.05.038","volume":"134","author":"JY Tan","year":"2023","unstructured":"Tan, J. Y., Tan, K. K. & AbuBakar, S. Differential cross-neutralization of dengue immune sera against Zika virus. Int. J. Infect. Dis. 134, S8 (2023).","journal-title":"Int. J. Infect. Dis."},{"key":"8793_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01669-z","volume":"8","author":"J Wen","year":"2017","unstructured":"Wen, J. et al. Dengue virus-reactive CD8(+) T cells mediate cross-protection against subsequent Zika virus challenge. Nat. Commun. 8, 1459 (2017).","journal-title":"Nat. Commun."},{"key":"8793_CR20","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.chom.2018.09.015","volume":"24","author":"AM Fowler","year":"2018","unstructured":"Fowler, A. M. et al. Maternally acquired zika antibodies enhance dengue disease severity in mice. Cell Host Microbe 24, 743\u2013750.e745 (2018).","journal-title":"Cell Host Microbe"},{"key":"8793_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05458-0","volume":"9","author":"JA Regla-Nava","year":"2018","unstructured":"Regla-Nava, J. A. et al. Cross-reactive Dengue virus-specific CD8(+) T cells protect against Zika virus during pregnancy. Nat. Commun. 9, 3042 (2018).","journal-title":"Nat. Commun."},{"key":"8793_CR22","doi-asserted-by":"publisher","unstructured":"Grifoni, A. et al. Prior dengue virus exposure shapes T cell immunity to Zika virus in humans. J Virol. 91, https:\/\/doi.org\/10.1128\/jvi.01469-17 (2017).","DOI":"10.1128\/jvi.01469-17"},{"key":"8793_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54146-9","volume":"15","author":"DP Shinde","year":"2024","unstructured":"Shinde, D. P. et al. Potential role of heterologous flavivirus immunity in preventing urban transmission of yellow fever virus. Nat. Commun. 15, 9728 (2024).","journal-title":"Nat. Commun."},{"key":"8793_CR24","doi-asserted-by":"publisher","unstructured":"Shinde, D. P. et al. Mechanisms of flavivirus cross-protection against yellow fever in a mouse model. Viruses 16, https:\/\/doi.org\/10.3390\/v16060836 (2024).","DOI":"10.3390\/v16060836"},{"key":"8793_CR25","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.3389\/fimmu.2019.02631","volume":"10","author":"B Agrawal","year":"2019","unstructured":"Agrawal, B. Heterologous immunity: role in natural and vaccine-induced resistance to infections. Front. Immunol. 10, 2631 (2019).","journal-title":"Front. Immunol."},{"key":"8793_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1126\/science.aal4365","volume":"356","author":"SV Bardina","year":"2017","unstructured":"Bardina, S. V. et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science 356, 175\u2013180 (2017).","journal-title":"Science"},{"key":"8793_CR27","doi-asserted-by":"publisher","first-page":"e0000175","DOI":"10.1371\/journal.pgph.0000175","volume":"2","author":"A Khan","year":"2022","unstructured":"Khan, A. et al. Majority of pediatric dengue virus infections in Kenya do not meet 2009 WHO criteria for dengue diagnosis. PLOS Glob. Public Health 2, e0000175 (2022).","journal-title":"PLOS Glob. Public Health"},{"key":"8793_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1458166","volume":"15","author":"Y Liang","year":"2024","unstructured":"Liang, Y. & Dai, X. The global incidence and trends of three common flavivirus infections (Dengue, yellow fever, and Zika) from 2011 to 2021. Front. Microbiol. 15, 1458166 (2024).","journal-title":"Front. Microbiol."},{"key":"8793_CR29","unstructured":"WHO. Disease Outbreak News; Dengue- Global situation, https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2023-DON518 (2024)."},{"key":"8793_CR30","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","volume":"496","author":"S Bhatt","year":"2013","unstructured":"Bhatt, S. et al. The global distribution and burden of dengue. Nature 496, 504\u2013507 (2013).","journal-title":"Nature"},{"key":"8793_CR31","doi-asserted-by":"publisher","unstructured":"Kuno, G. The absence of yellow fever in Asia: history, hypotheses, vector dispersal, possibility of YF in Asia, and other enigmas. Viruses 12, https:\/\/doi.org\/10.3390\/v12121349 (2020).","DOI":"10.3390\/v12121349"},{"key":"8793_CR32","doi-asserted-by":"publisher","unstructured":"Herrera, B. B. et al. Sustained specific and cross-reactive T cell responses to Zika and dengue virus NS3 in West Africa. J. Virol. 92, https:\/\/doi.org\/10.1128\/jvi.01992-17 (2018).","DOI":"10.1128\/jvi.01992-17"},{"key":"8793_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70338","volume":"97","author":"S Gallon","year":"2025","unstructured":"Gallon, S. et al. Seropositivity to dengue, Zika, yellow fever, and West Nile viruses in Senegal, West Africa. J. Med. Virol. 97, e70338 (2025).","journal-title":"J. Med. Virol."},{"key":"8793_CR34","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/infdis\/jix182","volume":"215","author":"BB Herrera","year":"2017","unstructured":"Herrera, B. B. et al. Continued transmission of Zika virus in humans in West Africa, 1992-2016. J. Infect. Dis. 215, 1546\u20131550 (2017).","journal-title":"J. Infect. Dis."},{"key":"8793_CR35","doi-asserted-by":"publisher","first-page":"e0149871","DOI":"10.1371\/journal.pone.0149871","volume":"11","author":"RW Wieten","year":"2016","unstructured":"Wieten, R. W. et al. A single 17D yellow fever vaccination provides lifelong immunity; characterization of yellow-fever-specific neutralizing antibody and T-cell responses after vaccination. PLoS ONE 11, e0149871 (2016).","journal-title":"PLoS ONE"},{"key":"8793_CR36","doi-asserted-by":"publisher","first-page":"12794","DOI":"10.1128\/JVI.01160-13","volume":"87","author":"EA James","year":"2013","unstructured":"James, E. A. et al. Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins. J. Virol. 87, 12794\u201312804 (2013).","journal-title":"J. Virol."},{"key":"8793_CR37","unstructured":"CDC. Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6423a5.htm (2015)."},{"key":"8793_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1099\/0022-1317-70-1-37","volume":"70","author":"CH Calisher","year":"1989","unstructured":"Calisher, C. H. et al. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J. Gen. Virol. 70, 37\u201343 (1989).","journal-title":"J. Gen. Virol."},{"key":"8793_CR39","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1016\/j.vaccine.2011.09.114","volume":"30","author":"FX Heinz","year":"2012","unstructured":"Heinz, F. X. & Stiasny, K. Flaviviruses and flavivirus vaccines. Vaccine 30, 4301\u20134306 (2012).","journal-title":"Vaccine"},{"key":"8793_CR40","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/00365540801995386","volume":"40","author":"E Ferenczi","year":"2008","unstructured":"Ferenczi, E. et al. Severe tick-borne encephalitis in a patient previously infected by West Nile virus. Scand. J. Infect. Dis. 40, 759\u2013761 (2008).","journal-title":"Scand. J. Infect. Dis."},{"key":"8793_CR41","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1099\/0022-1317-71-12-2909","volume":"71","author":"DM Morens","year":"1990","unstructured":"Morens, D. M. & Halstead, S. B. Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies. J. Gen. Virol. 71, 2909\u20132914 (1990).","journal-title":"J. Gen. Virol."},{"key":"8793_CR42","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1086\/315215","volume":"181","author":"DW Vaughn","year":"2000","unstructured":"Vaughn, D. W. et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181, 2\u20139 (2000).","journal-title":"J. Infect. Dis."},{"key":"8793_CR43","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1128\/JVI.02273-08","volume":"83","author":"M Lobigs","year":"2009","unstructured":"Lobigs, M., Larena, M., Alsharifi, M., Lee, E. & Pavy, M. Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus. J. Virol. 83, 2436\u20132445 (2009).","journal-title":"J. Virol."},{"key":"8793_CR44","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/S0264-410X(02)00743-0","volume":"21","author":"M Lobigs","year":"2003","unstructured":"Lobigs, M., Pavy, M. & Hall, R. Cross-protective and infection-enhancing immunity in mice vaccinated against flaviviruses belonging to the Japanese encephalitis virus serocomplex. Vaccine 21, 1572\u20131579 (2003).","journal-title":"Vaccine"},{"key":"8793_CR45","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/nm887","volume":"9","author":"J Mongkolsapaya","year":"2003","unstructured":"Mongkolsapaya, J. et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9, 921\u2013927 (2003).","journal-title":"Nat. Med."},{"key":"8793_CR46","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ebiom.2016.10.006","volume":"13","author":"A Elong Ngono","year":"2016","unstructured":"Elong Ngono, A. et al. Protective role of cross-reactive CD8 T cells against dengue virus infection. EBioMedicine 13, 284\u2013293 (2016).","journal-title":"EBioMedicine"},{"key":"8793_CR47","doi-asserted-by":"publisher","first-page":"E2046","DOI":"10.1073\/pnas.1305227110","volume":"110","author":"D Weiskopf","year":"2013","unstructured":"Weiskopf, D. et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc. Natl. Acad. Sci. USA 110, E2046\u2013E2053 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"8793_CR48","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.4049\/jimmunol.1001709","volume":"185","author":"LE Yauch","year":"2010","unstructured":"Yauch, L. E. et al. CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J. Immunol. 185, 5405\u20135416 (2010).","journal-title":"J. Immunol."},{"key":"8793_CR49","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.4049\/jimmunol.0801974","volume":"182","author":"LE Yauch","year":"2009","unstructured":"Yauch, L. E. et al. A protective role for dengue virus-specific CD8+ T cells. J. Immunol. 182, 4865\u20134873 (2009).","journal-title":"J. Immunol."},{"key":"8793_CR50","doi-asserted-by":"publisher","first-page":"e1007474","DOI":"10.1371\/journal.ppat.1007474","volume":"15","author":"A Elong Ngono","year":"2019","unstructured":"Elong Ngono, A. et al. CD4+ T cells promote humoral immunity and viral control during Zika virus infection. PLoS Pathog. 15, e1007474 (2019).","journal-title":"PLoS Pathog."},{"key":"8793_CR51","doi-asserted-by":"publisher","unstructured":"Grifoni, A. et al. T cell responses induced by attenuated flavivirus vaccination are specific and show limited cross-reactivity with other flavivirus species. J. Virol. 94, https:\/\/doi.org\/10.1128\/jvi.00089-20 (2020).","DOI":"10.1128\/jvi.00089-20"},{"key":"8793_CR52","doi-asserted-by":"publisher","first-page":"e0006530","DOI":"10.1371\/journal.pntd.0006530","volume":"12","author":"BB Herrera","year":"2018","unstructured":"Herrera, B. B. et al. A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals. PLoS Negl. Trop. Dis. 12, e0006530 (2018).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"8793_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1522733","volume":"13","author":"BB Herrera","year":"2025","unstructured":"Herrera, B. B. et al. Pre-pandemic cross-reactive antibody and cellular responses against SARS-CoV-2 among female sex workers in Dakar, Senegal. Front. Public Health 13, 1522733 (2025).","journal-title":"Front. Public Health"},{"key":"8793_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aar4297","volume":"4","author":"WAA Saron","year":"2018","unstructured":"Saron, W. A. A. et al. Flavivirus serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T cells. Sci. Adv. 4, eaar4297 (2018).","journal-title":"Sci. Adv."},{"key":"8793_CR55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12250-020-00230-5","volume":"36","author":"C Lei","year":"2021","unstructured":"Lei, C., Yang, J., Hu, J. & Sun, X. On the calculation of TCID(50) for quantitation of virus infectivity. Virol. Sin. 36, 141\u2013144 (2021).","journal-title":"Virol. Sin."},{"key":"8793_CR56","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.3390\/v13071352","volume":"13","author":"M Dallner","year":"2021","unstructured":"Dallner, M., Harlow, J. & Nasheri, N. Human coronaviruses do not transfer efficiently between surfaces in the absence of organic materials. Viruses 13, 1352 (2021).","journal-title":"Viruses"},{"key":"8793_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1226-z","volume":"15","author":"E Alm","year":"2015","unstructured":"Alm, E., Lindegren, G., Falk, K. I. & Lagerqvist, N. One-step real-time RT-PCR assays for serotyping dengue virus in clinical samples. BMC Infect. Dis. 15, 493 (2015).","journal-title":"BMC Infect. Dis."},{"key":"8793_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70282","volume":"97","author":"PB Tonto","year":"2025","unstructured":"Tonto, P. B. et al. Seroprevalence of chikungunya and O\u2019nyong-nyong viruses in Senegal, West Africa. J. Med. Virol. 97, e70282 (2025).","journal-title":"J. Med. Virol."},{"key":"8793_CR59","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jviromet.2017.09.014","volume":"249","author":"K Laposova","year":"2017","unstructured":"Laposova, K., Oveckova, I. & Tomaskova, J. A simple method for isolation of cell-associated viral particles from cell culture. J. Virol. Methods 249, 194\u2013196 (2017).","journal-title":"J. Virol. Methods"},{"key":"8793_CR60","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2024.39.e35","volume":"39","author":"F Habibzadeh","year":"2024","unstructured":"Habibzadeh, F. Data distribution: normal or abnormal? J. Korean Med. Sci. 39, e35 (2024).","journal-title":"J. Korean Med. Sci."},{"key":"8793_CR61","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12985-022-01786-2","volume":"19","author":"P Pan","year":"2022","unstructured":"Pan, P. et al. Characteristics of lymphocyte subsets and cytokine profiles of patients with COVID-19. Virol. J. 19, 57 (2022).","journal-title":"Virol. J."},{"key":"8793_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13053","volume":"17","author":"PB Tonto","year":"2023","unstructured":"Tonto, P. B. et al. High prevalence of IgE sensitization to inactivated influenza vaccines, yet robust IgG4 responses, in a healthy pediatric population. Influenza Other Respir. Viruses 17, e13053 (2023).","journal-title":"Influenza Other Respir. Viruses"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08793-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08793-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08793-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T11:32:21Z","timestamp":1756899141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08793-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8793"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-08793-3","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: BBH is a co-founder of Mir Biosciences, Inc., a biotechnology company focused on T cell-based diagnostics and vaccines for infectious diseases, cancer, and autoimmunity. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1334"}}